Donald Hilty
Psychiatry · Sacramento, CANPI 1346222734
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,300 of the $10,112 with a category attached, or 82.1%. Alkermes, Inc. accounts for 95.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $9,587 and has fallen 99.7% since, to $25 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $326.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$10K
- Otsuka America Pharmaceutical, Inc.$116
- Johnson & Johnson$110
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$105
- AbbVie$86
- Janssen Scientific Affairs, LLC$36
- plus $43 from 2 others
What the payments were for
- Consulting fees$8,30082%
- Travel & lodging$8899%
- Food & beverage$9239%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 11 | $9,616 |
| Otsuka America Pharmaceutical, Inc. | 5 | $116 |
| Johnson & Johnson | 4 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $105 |
| AbbVie | 3 | $86 |
| Janssen Scientific Affairs, LLC | 1 | $36 |
| Indivior Inc. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$37,111
- ARISTADA INITIO$9,278
How this compares
$10,112 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 14 | $1,110 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $621 |
| Oxcarbazepine | 16 | $586 |
| Olanzapine | 31 | $545 |
| Quetiapine Fumarate | 23 | $223 |
| Risperidone | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Sacramento
- David SmithSacramento$588K
- Jacob AdamsSacramento$419K
- Robert McCarronSacramento$136K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.